Featured Publications
Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder
Farhat L, Flores J, Avila-Quintero V, Polanczyk G, Cipriani A, Furukawa T, Bloch M, Cortese S. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry 2024, 81: 157-166. PMID: 37878348, PMCID: PMC10600727, DOI: 10.1001/jamapsychiatry.2023.3985.Peer-Reviewed Original ResearchAttention-deficit/hyperactivity disorderLicensed dosesDose-response curveStimulant dosesClinical trialsTreatment outcomesRisk benefitHyperactivity disorderReduction of symptomsDrug Administration recommendationsAdverse eventsDose escalationLanguage restrictionsAdministration recommendationsUS FoodSymptomsDosesAdditional riskData extractionAdditional reductionADHD symptomsAdultsGreater reductionStimulantsRisk
2020
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitors